Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2017 Mar 30;15(10):1580–1588.e3. doi: 10.1016/j.cgh.2017.03.031

Figure 2.

Figure 2

Kaplan-Meier cumulative probability curves of treatment failure in patients undergoing either reactive (dotted line) or proactive therapeutic drug monitoring (TDM) (solid line) based on the first infliximab (IFX) concentration measured (A), stratified also by the type of IBD, Crohn’s disease (B) or ulcerative colitis (C).